Molecular subtypes in pancreatic cancer: from academic promise to clinical reality - PubMed
3 days ago
- #Pancreatic Cancer
- #Precision Medicine
- #Molecular Subtypes
- Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate below 12%.
- Transcriptomic analyses identified molecular subtypes: classical/progenitor (GATA6-high) and basal-like/squamous (GATA6-low).
- Clinical adoption of subtypes is limited by reproducibility, technical challenges, and implementation barriers.
- Multi-omics integration has deepened understanding but revealed complexity in classification frameworks.
- Immunohistochemical assessment of GATA6 provides strong prognostic information in treatment-naive patients.
- Therapy-induced molecular plasticity can compromise the reliability of static biomarkers.
- Single-cell RNA sequencing and spatial transcriptomics clarify subtype heterogeneity and immune contexture.
- Review synthesizes PDAC subtyping developments, translational hurdles, and proposes a clinical implementation roadmap.